8-K: Sagimet Biosciences Reports Q1 2025 Financial Results and Advances Clinical Programs

Sagimet Biosciences announced its first quarter 2025 financial results and provided corporate updates, including plans to initiate a Phase 1 clinical trial for a combination therapy targeting MASH.

Summary

• Sagimet Biosciences reported its financial results for the quarter ended March 31, 2025.
• The company plans to initiate a Phase 1 clinical trial in the second half of 2025 to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom, with data readout expected in the first half of 2026.
• End-of-Phase 2 interactions with the FDA were successfully completed in October 2024, supporting the advancement of denifanstat into Phase 3 in MASH.
• Sagimet is exploring various alternatives to fund the ongoing development of denifanstat as a monotherapy.
• Effective May 6, 2025, George Kemble transitioned from Executive Chairman to non-executive Chair of the Board, and Beth Seidenberg was appointed Lead Independent Director.
• Merdad Parsey will step off the Board effective June 9, 2025.
• Cash, cash equivalents, and marketable securities as of March 31, 2025, were $144.6 million.
• Research and development expense for the quarter was $15.3 million, compared to $5.3 million for the first quarter of 2024.
• General and administrative expense was $4.5 million, compared to $3.5 million for the first quarter of 2024.
• Net loss for the quarter was $18.2 million, compared to $6.6 million for the first quarter of 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress in its clinical programs, but the need for additional funding and the increased net loss are concerns.

Positives

• Successful completion of end-of-Phase 2 interactions with the FDA supports the advancement of denifanstat into Phase 3 in MASH.
• Preclinical data demonstrates a synergistic effect of combining a FASN inhibitor with resmetirom on liver disease markers.
• IND clearance received for TVB-3567, allowing initiation of a Phase 1 clinical trial in acne.
• Ascletis, Sagimet's partner in China, completed enrollment in a Phase 3 clinical trial of denifanstat for acne and expects topline results in Q2 2025.

Negatives

• Sagimet does not intend to initiate Phase 3 trials in F2/F3 MASH patients until it has sufficient funding.
• The company reported a net loss of $18.2 million for the quarter ended March 31, 2025, compared to a net loss of $6.6 million for the same period in 2024.
• Increased research and development expenses from $5.3 million to $15.3 million compared to the same quarter last year.

Risks

• The company's ability to secure funding for Phase 3 trials of denifanstat is uncertain.
• Clinical trial outcomes are inherently uncertain and may not be positive.
• The company's estimates regarding its capital requirements may be inaccurate.
• The company faces risks related to maintaining and enforcing adequate intellectual property protection.

Future Outlook

Sagimet anticipates initiating a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of denifanstat and resmetirom in the second half of 2025, with an anticipated data readout in the first half of 2026. Ascletis expects to announce topline results from its Phase 3 clinical trial of denifanstat for acne in China in the second quarter of 2025. Sagimet is also planning to initiate a first-in-human Phase 1 clinical trial of TVB-3567 in acne in the second half of 2025.

Management Comments

• David Happel, Chief Executive Officer of Sagimet, stated that further development of denifanstat in MASH, including as part of a combination program, could potentially offer an opportunity to serve patient groups with the strongest need of treatment including those with stage 4 fibrosis.
• Rohit Loomba, M.D., M.H.Sc., Professor of Medicine, Chief, Division of Gastroenterology and Hepatology, and Director, MASLD Research Center, University of California San Diego, said he is excited to see Sagimet initiate development of a combination of denifanstat and resmetirom with this Phase 1 PK trial which will potentially answer important questions about the compatibility of these two molecules in humans.

Industry Context

Sagimet's focus on MASH and acne addresses significant unmet needs in the biopharmaceutical industry. The company's strategy of combining denifanstat with resmetirom reflects a growing trend towards combination therapies in liver disease. The acne market is also a large and competitive space, with dermatologists open to new therapies.

Comparison to Industry Standards

• The 80% improvement in NAS (NAFLD Activity Score) by histologic analysis observed in preclinical data for the combination of a FASN inhibitor and resmetirom is a promising result compared to monotherapy treatments.
• The successful completion of end-of-Phase 2 interactions with the FDA is a positive step towards Phase 3 development, similar to other companies advancing MASH therapies.
• Sagimet's cash position of $144.6 million provides a runway for ongoing clinical development, but the company needs to secure additional funding for Phase 3 trials.

Management Changes

Stakeholder Impact

• Shareholders: The need for additional funding may dilute existing shareholders' equity.
• Employees: The company's ability to continue clinical development depends on securing funding, which could impact job security.
• Patients: Successful development of denifanstat and TVB-3567 could provide new treatment options for MASH and acne.

Next Steps

• Initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of denifanstat and resmetirom in the second half of 2025.
• Await topline results from Ascletis' Phase 3 clinical trial of denifanstat for acne in China in the second quarter of 2025.
• Initiate a first-in-human Phase 1 clinical trial of TVB-3567 in acne in the second half of 2025.
• Explore various alternatives to fund the ongoing development of denifanstat as a monotherapy.

Key Dates

Keywords

denifanstat, MASH, FASN inhibitor, resmetirom, clinical trial, TVB-3567, acne, Ascletis, Phase 3, Phase 1, financial results, Sagimet Biosciences